Emtricitabine/TAF is noninferior to emtricitabine/tenofovir disoproxil fumarate in men who have sex with men.
Emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) was the only option for HIV preexposure prophylaxis (PrEP) until 2019, when FTC/tenofovir alafenamide (TAF) was approved. This approval was based on results from DISCOVER, an ongoing manufacturer-sponsored trial, which have now been published. The double-blind, randomized phase 3 trial enrolled cisgender men who have sex with men (MSM) and transgender women (TGW). Participants had to have a history of recent condomless anal intercourse with >1 partner or bacterial sexually transmitted infection.
A total of 2694 participants received FTC/TAF and 2693 received FTC/TDF. Only 9% of participants were Black and just 1% were TGW. The main results were as follows:
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)